Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key psoriatic arthritis patient populations covering 171 countries and…
Clarivate Epidemiology’s coverage of gastric cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology's coverage of psoriatic arthritis (PsA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsA for…
Clarivate Epidemiology's coverage of cystic fibrosis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of cystic fibrosis…
A wide array of drugs are available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially…
The HIV therapy market is crowded with many approved antiretroviral therapies (ARVs). Growth in this market is being driven by the increasing acceptance of new, high-priced ARVs, particularly the…
*NOTE: the brochure was already reviewed by an editor* MARKET OUTLOOK Idiopathic pulmonary fibrosis (IPF) is a type of lung disease characterized by the thickening and stiffening of tissues in…
MARKET OUTLOOK The HIV therapy market is crowded with many approved antiretroviral (ARV) therapies. Growth in this market is being driven by increasing acceptance of new, high-priced ARVs,…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key thyroid cancer patient populations covering 171 countries and more than…
Clarivate Epidemiology’s coverage of thyroid cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of …
Clarivate Epidemiology’s coverage of thyroid cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have moved earlier in the disease spectrum to…
In 2019, sales of branded biologics in ophthalmology reached almost $9 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2019-2029 forecast period,…
In 2020, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $100 billion in the major pharmaceutical markets under study (United…